1. Home
  2. SPHL vs XBIO Comparison

SPHL vs XBIO Comparison

Compare SPHL & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Springview Holdings Ltd Class A Ordinary Shares

SPHL

Springview Holdings Ltd Class A Ordinary Shares

HOLD

Current Price

$2.33

Market Cap

6.1M

ML Signal

HOLD

Logo Xenetic Biosciences Inc.

XBIO

Xenetic Biosciences Inc.

HOLD

Current Price

$3.10

Market Cap

7.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPHL
XBIO
Founded
2002
N/A
Country
Singapore
United States
Employees
71
2
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.1M
7.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SPHL
XBIO
Price
$2.33
$3.10
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
9.4K
15.0K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$2.81
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$1.90
52 Week High
$25.11
$13.93

Technical Indicators

Market Signals
Indicator
SPHL
XBIO
Relative Strength Index (RSI) 40.98 51.64
Support Level $2.18 $2.88
Resistance Level $3.11 $3.12
Average True Range (ATR) 0.21 0.19
MACD 0.00 -0.04
Stochastic Oscillator 15.59 23.11

Price Performance

Historical Comparison
SPHL
XBIO

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

Share on Social Networks: